News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

University of Pennsylvania Should Rethink Over-Hyped Press Releases



1/11/2017 7:07:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Back in 2012, a press release was issued by the Perelman School of Medicine at the University of Pennsylvania which had profound medical implications for treating arthritic pain in patients with heart disease. Entitled “NSAIDs and Cardiovascular Risk Explained, According to Studies from the Perelman School of Medicine,” the release was quite damning about the use of a certain class of non-steroidal anti-inflammatory drugs (NSAIDs) – the COX-2 inhibitors – not just in patients with cardiovascular (CV) risk but even arthritis patients without such risk. The COX-2 inhibitors in question were Pfizer’s Celebrex (generic name: celecoxib) and Merck’s Vioxx, the latter in fact having already been pulled from the market due to increasing the risk of heart attacks during extended use. Here’s what Penn had to say.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES